US 2026/0232824 A1Published application

Anti-cd180 binding molecules and uses thereof

AssigneeChampions Oncology, Inc.

InventorsGarima KAUSHIK, Marina BELL, Kakajan KOMUROV, Michael Ritchie

Life of this patent

Estimating the term…

Loading patent…

Abstract

The present disclosure provides anti-CD180 binding molecules and uses thereof. In one embodiment, the anti-CD180 binding molecules are anti-CD180 antibodies. Also provided are anti-CD180 antibody-drug conjugates (ADCs) comprising a CD180-high expressing tumor-targeting monoclonal antibody or antigen-binding fragment thereof, a cytotoxic drug payload and a linker moiety conjugating the CD180-high expressing tumor-targeting antibody or the antigen-binding fragment thereof to the cytotoxic drug payload. The anti-CD180 antibodies or the antigen binding fragments thereof, and the ADCs comprising the anti-CD180 antibodies, or the antigen binding fragments thereof are useful in treating diseases, such as acute myeloid leukemia, mantle cell lymphoma, multiple myeloma. follicular lymphoma, B-acute lymphoblastic leukemia, or diffuse large B-cell lymphoma.

Claims59

Dependent claims

An anti-CD180 antibody-drug conjugate (ADC) comprising a CD180-high expressing tumor-targeting monoclonal antibody or antigen-binding fragment thereof, a cytotoxic drug payload and a linker moiety conjugating the CD180-high expressing tumor-targeting antibody or the antigen-binding fragment thereof to the cytotoxic drug payload, wherein the anti-CD180 antibody or antigen-binding fragment thereof comprises a set of three heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and a corresponding set of three light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the set of HCDR1, HCDR2 and HCDR3 and the set of corresponding LCDR1, LCDR2 and LCDR3 each comprise the amino acid sequences:

HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1-3 and LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:
4-6;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1-3 and LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:
4, 5, and 15;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 24, and 25 and LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:
4, 5, and 26;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 35, and 25 and LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:
4, 5, and 26;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 44, and 25 and LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:
4, 5, and 45;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
54-56 and LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:
57-59;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
68-70 and LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:
57, 58, and 71;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 24, and 25 and LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:
80-82;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 35, and 25 and LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:
91-93;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 102, and 25 and LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:
4, 103, and 6;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 24, and 25 and LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:
112, 5, and 113;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 35, and 25 and LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:
4-6;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 44, and 25 and LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:
4, 5, and 130;
or
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 24, and 25 and LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:
4-6.

40 more elements

An isolated anti-CD180 binding molecule comprising a set of three heavy chain complementarity determining regions HCDR1, HCDR2 and HCDR3, and a corresponding set of three light chain complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein the set of HCDR1, HCDR2 and HCDR3 and the set of corresponding LCDR1, LCDR2 and LCDR3 each comprise the amino acid sequences:

HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1-3 and LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:
4-6;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1-3 and SEQ ID NOs:
4, 5, and 15;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 24, and 25 and SEQ ID NOs:
4, 5, and 26;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 35, and 25 and SEQ ID NOs:
4, 5, and 26;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 44, and 25 and SEQ ID NOs:
4, 5, and 45;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
54-56 and SEQ ID NOs:
57-59;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
68-70 and SEQ ID NOs:
57, 58, and 71;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 24, and 25 and SEQ ID NOs:
80-82;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 35, and 25 and SEQ ID NOs:
91-93;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 102, and 25 and SEQ ID NOs:
4, 103, and 6;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 24, and 25 and SEQ ID NOs:
112, 5, and 113;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 35, and 25 and SEQ ID NOs:
4-6;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 44, and 25 and SEQ ID NOs:
4, 5, and 130;
HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:
1, 24, and 25 and SEQ ID NOs:
4-6.

39 more elements

Dependencies are inferred from the claim text.

Facts

Application: 19/152,391Filed 2 Feb 2024
Priority: 3 Feb 2023
Published: 13 Aug 2026
Term ends: Not estimatedThe source records don’t support an estimate.

Classification16 codes

A61K 47/68035
Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates: the drug being a pyrrolobenzodiazepine
A61P 35/00
Antineoplastic agents
A61K 47/6849
The modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site: the antibody targeting a receptor, a cell…
A61K 47/6867
The antibody targeting a determinant of a tumour cell: the tumour determinant being from a cell of a blood cancer